title: Ibrutinib: another weapon in our arsenal against lympho-proliferative disorders.
abstract: In Volume 16, issue 12 of Expert Opinion on Pharmacotherapy, an important article on the new drug ibrutinib was published. This new drug promises to further improve outcome in the treatment of several lympho-proliferative disorders. In this editorial, the most important findings of the article looking particularly to the integration of ibrutinib in current clinical practice will be summarized. Finally this editorial will focus on the next challenges for scientists and physicians in the treatment of lympho-proliferative disorders.
authors.affiliation: a Unità Operativa Ematologia e Centro Trapianti , Ospedale Oncologico di Riferimento Regionale "Armando Businco" , Cagliari 09121 , Italy.
authors.forename: Maria Giuseppina
authors.initials: MG
authors.lastname: Cabras
authors.affiliation: a Unità Operativa Ematologia e Centro Trapianti , Ospedale Oncologico di Riferimento Regionale "Armando Businco" , Cagliari 09121 , Italy.
authors.forename: Emanuele
authors.initials: E
authors.lastname: Angelucci
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D008232:Lymphoproliferative Disorders / Q000188:drug therapy*; D010880:Piperidines; D011720:Pyrazoles / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D010880:Piperidines; D011720:Pyrazoles; D011743:Pyrimidines; C551803:ibrutinib; D000225:Adenine
keywords: Waldenström’s macroglobulinemia; chronic lymphocytic leukemia; ibrutinib; non-Hodgkin lymphoma